GlassScriptPhysician profile
Marc A Olivier
NPI 1427088350
$4,078.06
in general payments reported to CMS, 2019-2025
30 companies · $849 in 2025
The $849 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $350 · 2021: $409 · 2022: $737 · 2023: $625 · 2024: $666 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134 · Education: $5.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.96 |
| Education | $5.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $712.90 | 2021-2025 | |
| Vifor Pharma, INC. | $385.49 | 2019-2023 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $357.01 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $309.81 | 2019-2025 | Jynarque |
| Amgen INC. | $286.87 | 2019-2025 | Tavneos, Krystexxa |
| Fresenius USA Marketing, INC. | $267.51 | 2019-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $241.20 | 2021-2024 | Benlysta, Jesduvroq |
| Baxter Healthcare | $236.47 | 2020-2024 | |
| Vantive US Healthcare LLC | $149.33 | 2025 | Renal - Pd |
| Takeda Pharmaceuticals U.S.A., INC. | $132.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $128.38 | 2023-2025 | |
| Novo Nordisk INC | $104.25 | 2024-2025 | Wegovy, Ozempic |
| Opko Pharmaceuticals, LLC | $95.02 | 2019-2022 | |
| Horizon Therapeutics Plc | $75.83 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $72.91 | 2023-2025 | Tarpeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.55 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $53.00 | 2023 | Lupkynis |
| Genzyme Corporation | $49.35 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $44.37 | 2025 | Acthar |
| Ardelyx, INC. | $43.19 | 2023-2025 | Ibsrela |
| Travere Therapeutics, INC. | $36.91 | 2024-2025 | |
| Leadiant Biosciences, INC. | $35.53 | 2023 | Cystaran |
| Akebia Therapeutics INC | $30.40 | 2019-2021 | |
| Veloxis Pharmaceuticals, INC. | $29.83 | 2025 | Envarsus |
| Biomerieux INC | $27.54 | 2020 | |
| Lilly USA, LLC | $26.14 | 2023-2024 | Jardiance |
| Cormedix INC. | $23.21 | 2025 | Defencath |
| Alexion Pharmaceuticals, INC. | $21.64 | 2022 | |
| Ani Pharmaceuticals, INC. | $19.55 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Olivier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.